Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties

References

• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–17. doi:10.1038/d41573-021-00079-7.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022;14(1):2123299. doi:10.1080/19420862.2022.2123299.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11–26. doi:10.1007/s40259-019-00392-z.
   PubMed Web of Science ®Google Scholar
• Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, function, and therapeutic use of IgM antibodies. Antibodies. 2020;9(4):1–35. doi:10.3390/antib9040053.
   Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. doi:10.1038/nrd.2016.268.
   PubMed Web of Science ®Google Scholar
• Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540–45. doi:10.1038/s41587-020-0512-5.
   PubMed Web of Science ®Google Scholar
• Kelley B, de Moor P, Douglas K, Renshaw T, Traviglia S. Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products. Curr Opin Biotechnol. 2022;78:102798. doi:10.1016/j.copbio.2022.102798.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, Sivasubramanian A, Vásquez M, Xu Y. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019;11(1):45–57. doi:10.1080/19420862.2018.1548233.
   PubMed Web of Science ®Google Scholar
• Whitaker N, Xiong J, Pace SE, Kumar V, Middaugh CR, Joshi SB, Volkin DB. A formulation development approach to identify and select stable ultra–high-concentration monoclonal antibody formulations with reduced viscosities. J Pharm Sci. 2017;106(11):3230–41. doi:10.1016/j.xphs.2017.06.017.
   PubMed Web of Science ®Google Scholar
• Rabia LA, Zhang Y, Ludwig SD, Julian MC, Tessier PM, Daggett V. Net charge of antibody complementarity-determining regions is a key predictor of specificity. Protein Engineering, Design and Selection. 2018;31(11):409–18. doi:10.1093/protein/gzz002.
   PubMed Web of Science ®Google Scholar
• Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules. 2011;16(5):3675–700. doi:10.3390/molecules16053675.
   PubMed Web of Science ®Google Scholar
• Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101(1):102–15. doi:10.1002/jps.22758.
   PubMed Web of Science ®Google Scholar
• von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5(5):646–54. doi:10.4161/mabs.25632.
   PubMed Web of Science ®Google Scholar
• Starr CG, Tessier PM. Selecting and engineering monoclonal antibodies with drug-like specificity. Curr Opin Biotechnol. 2019;60:119–27. doi:10.1016/j.copbio.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu L, Gupta P, Desai AA, Smith MD, Rabia LA, Ludwig SD, Tessier PM. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity. Mol Pharm. 2020;17(7):2555–69. doi:10.1021/acs.molpharmaceut.0c00257.
   PubMedGoogle Scholar
• Wolf Pérez AM, Lorenzen N, Vendruscolo M, Sormanni P. Assessment of therapeutic antibody developability by combinations of in vitro and in silico methods. Therapeutic Antibodies Methods in Molecular Biology. New York, NY: Humana: 2022;57–113. doi:10.1007/978-1-0716-1450-1_4.
   Google Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. MAbs. 2020;12(1):1743053. doi:10.1080/19420862.2020.1743053.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Wu L, Gupta P, Tessier PM. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. MAbs. 2021;13(1):1895540. doi:10.1080/19420862.2021.1895540.
   PubMed Web of Science ®Google Scholar
• Kumar S, Roffi K, Tomar DS, Cirelli D, Luksha N, Meyer D, Mitchell J, Allen MJ, Li L , et al. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity. Protein Engineering, Design and Selection. 2018;31(7–8):313–25. doi:10.1093/protein/gzy020.
   PubMed Web of Science ®Google Scholar
• Rabia LA, Desai AA, Jhajj HS, Tessier PM. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem Eng J. 2018;137:365–74. doi:10.1016/j.bej.2018.06.003.
   PubMed Web of Science ®Google Scholar
• Tiller KE, Li L, Kumar S, Julian MC, Garde S, Tessier PM. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs. Journal of Biological Chemistry. 2017;292(40):16638–52. doi:10.1074/jbc.M117.783837.
   PubMed Web of Science ®Google Scholar
• Hoover JM, Prinslow EG, Teigler JE, Truppo MD, la Porte SL. Therapeutic antibody discovery. In: Remington: the science and practice of pharmacy. Cambridge, MA: Academic Press; 2020. p. 417–36.
   Google Scholar
• Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo Vadis? J Pharm Sci. 2022;111(4):861–67. doi:10.1016/J.XPHS.2021.11.008.
   PubMed Web of Science ®Google Scholar
• Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523–32. doi:10.4161/mabs.27398.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2020;6(32):eabb0372. doi:10.1126/sciadv.abb0372.
   PubMed Web of Science ®Google Scholar
• Svilenov HL, Winter G. Formulations that suppress aggregation during long-term storage of a bispecific antibody are characterized by high refoldability and colloidal stability. J Pharm Sci. 2020;109(6):2048–58. doi:10.1016/j.xphs.2020.03.011.
   PubMed Web of Science ®Google Scholar
• Baek Y, Singh N, Arunkumar A, Borys M, Li ZJ, Zydney AL. Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: effects of physical properties. Biotechnol Bioeng. 2017;114(9):2057–65. doi:10.1002/bit.26326.
   PubMed Web of Science ®Google Scholar
• Clarkson BR, Schön A, Freire E. Conformational stability and self-association equilibrium in biologics. Drug Discov Today. 2016;21(2):342–47. doi:10.1016/j.drudis.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Roberts CJ. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol. 2014;32(7):372–80. doi:10.1016/j.tibtech.2014.05.005.
   PubMed Web of Science ®Google Scholar
• Mazzer AR, Perraud X, Halley J, O’Hara J, Bracewell DG. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015;1415:83–90. doi:10.1016/j.chroma.2015.08.068.
   PubMed Web of Science ®Google Scholar
• Nejadnik MR, Randolph TW, Volkin DB, Schöneich C, Carpenter JF, Crommelin DJA, Jiskoot W. Postproduction handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci. 2018;107(8):2013–19. doi:10.1016/j.xphs.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75. doi:10.1007/s11095-009-0045-6.
   PubMed Web of Science ®Google Scholar
• Gentiluomo L, Svilenov HL, Augustijn D, El Bialy I, Greco ML, Kulakova A, Indrakumar S, Mahapatra S, Morales MM, Pohl C. Advancing therapeutic protein discovery and development through comprehensive computational and biophysical characterization. Mol Pharm. 2020;17(2):426–40. doi:10.1021/acs.molpharmaceut.9b00852.
   PubMedGoogle Scholar
• Koepf E, Eisele S, Schroeder R, Brezesinski G, Friess W. Notorious but not understood: how liquid-air interfacial stress triggers protein aggregation. Int J Pharm. 2018;537(1–2):202–12. doi:10.1016/j.ijpharm.2017.12.043.
   PubMedGoogle Scholar
• Cunningham O, Scott M, Zhou ZS, Finlay WJJ. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. MAbs. 2021;13(1):1999195. doi:10.1080/19420862.2021.1999195.
   PubMed Web of Science ®Google Scholar
• Ausserwöger H, Schneider MM, Herling TW, Arosio P, Invernizzi G, Knowles TPJ, Lorenzen N. Non-specificity as the sticky problem in therapeutic antibody development. Nat Rev Chem. 2022;6(12):844–61. doi:10.1038/s41570-022-00438-x.
   PubMed Web of Science ®Google Scholar
• Narayanan H, Dingfelder F, Butté A, Lorenzen N, Sokolov M, Arosio P. Machine learning for biologics: opportunities for protein engineering, developability, and formulation. Trends Pharmacol Sci. 2021;42(3):151–65. doi:10.1016/j.tips.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm. 2015;12(4):1005–17. doi:10.1021/mp400666b.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–97. doi:10.1038/256495a0.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, Lee -C-C, Tsai H-Z, Li H-J, Wu H-C. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1–30. doi:10.1186/s12929-019-0592-z.
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Greiff V, Karatt-Vellatt A, Muyldermans S, Jenkins TP. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. Trends Biotechnol. 2021;39(12):1263–73. doi:10.1016/j.tibtech.2021.03.003.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Ge X, Miklos AE, Hughes RA, Kang SH, Hoi KH, Chrysostomou C, Hunicke-Smith SP, Iverson BL, Tucker PW, et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol. 2010;28(9):965–69. doi:10.1038/nbt.1673.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–49. doi:10.1038/s41586-020-2548-6.
   PubMed Web of Science ®Google Scholar
• Valldorf B, Hinz SC, Russo G, Pekar L, Mohr L, Klemm J, Doerner A, Krah S, Hust M, Zielonka S, et al. Antibody display technologies: selecting the cream of the crop. Biol Chem. 2022;403(5):455–77. doi:10.1515/hsz-2020-0377.
   PubMed Web of Science ®Google Scholar
• Kaleli NE, Karadag M, Kalyoncu S. Phage display derived therapeutic antibodies have enriched aliphatic content: insights for developability issues. Proteins: Structure, Function and Bioinformatics. 2019;87(7):607–18. doi:10.1002/prot.25685.
   PubMed Web of Science ®Google Scholar
• Reis Teixeira A A, Erasmus MF, D’Angelo S, Naranjo L, Ferrara F, Leal-Lopes C, Durrant O, Galmiche C, Morelli A, Scott-Tucker A, et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. MAbs. 2021;13(1):1980942. doi:10.1080/19420862.2021.1980942.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Le D, Zhao J, Wittrup KD. Reduction of nonspecificity motifs in synthetic antibody libraries. J Mol Biol. 2018;430(1):119–30. doi:10.1016/j.jmb.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Teixeira AAR, D’Angelo S, Erasmus MF, Leal-Lopes C, Ferrara F, Spector LP, Naranjo L, Molina E, Max T, DeAguero A, et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs. MAbs. 2022;14(1):2115200. doi:10.1080/19420862.2022.2115200.
   PubMed Web of Science ®Google Scholar
• Shin JE, Riesselman AJ, Kollasch AW, McMahon C, Simon E, Sander C, Manglik A, Kruse AC, Marks DS. Protein design and variant prediction using autoregressive generative models. Nat Commun. 2021;12(1):1–11. doi:10.1038/s41467-021-22732-w.
   PubMed Web of Science ®Google Scholar
• Jung S, Honegger A, Plückthun A. Selection for improved protein stability by phage display. J Mol Biol. 1999;294(1):163–80. doi:10.1006/jmbi.1999.3196.
   PubMed Web of Science ®Google Scholar
• Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol. 2000;18(7):754–59. doi:10.1038/77325.
   PubMed Web of Science ®Google Scholar
• Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22(9):1161–65. doi:10.1038/nbt1000.
   PubMed Web of Science ®Google Scholar
• Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012;109(27):10879–84. doi:10.1073/pnas.1202866109.
   PubMed Web of Science ®Google Scholar
• Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol. 2008;376(4):926–31. doi:10.1016/j.jmb.2007.10.075.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Zhao J, Le D, Wittrup KD. Nonspecificity in a nonimmune human scFv repertoire. MAbs. 2017;9(7):1029–35. doi:10.1080/19420862.2017.1356528.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, Torrey J, Thomas J, Bobrowicz P, Vásquez M. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool. Protein Engineering, Design and Selection. 2013;26(10):663–70. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Mason DM, Weber CR, Parola C, Meng SM, Greiff V, Kelton WJ, Reddy ST. High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis. Nucleic Acids Res. 2018;46(14):7436–49. doi:10.1093/nar/gky550.
   PubMed Web of Science ®Google Scholar
• Parthiban K, Perera RL, Sattar M, Huang Y, Mayle S, Masters E, Griffiths D, Surade S, Leah R, Dyson MR, et al. A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing. MAbs. 2019;11(5):884–98. doi:10.1080/19420862.2019.1618673.
   PubMed Web of Science ®Google Scholar
• Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335. doi:10.1080/19420862.2020.1829335.
   PubMed Web of Science ®Google Scholar
• Tiller KE, Chowdhury R, Li T, Ludwig SD, Sen S, Maranas CD, Tessier PM. Facile affinity maturation of antibody variable domains using natural diversity mutagenesis. Front Immunol. 2017;8:986. doi:10.3389/fimmu.2017.00986.
   PubMed Web of Science ®Google Scholar
• Ki JJ, Min JS, Iverson BL, Georgiou G. APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering. Proc Natl Acad Sci U S A. 2007;104(20):8247–52. doi:10.1073/pnas.0702650104.
   PubMed Web of Science ®Google Scholar
• Waraho-Zhmayev D, Meksiriporn B, Portnoff AD, DeLisa MP, Bradbury A. Optimizing recombinant antibodies for intracellular function using hitchhiker-mediated survival selection. Protein Engineering, Design and Selection. 2014;27(10):351–58. doi:10.1093/protein/gzu038.
   PubMed Web of Science ®Google Scholar
• Lombana TN, Dillon M, Bevers J, Spiess C. Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system. Sci Rep. 2015;5(1):1–14. doi:10.1038/srep17488.
   Google Scholar
• Moghaddam-Taaheri P, Ikonomova SP, Gong Z, Wisniewski JQ, Karlsson AJ. Bacterial inner-membrane display for screening a library of antibody fragments. Journal of Visualized Experiments. 2016;116:e54583. doi:10.3791/54583.
   Google Scholar
• Esvelt KM, Carlson JC, Liu DR. A system for the continuous directed evolution of biomolecules. Nature. 2011;472(7344):499–503. doi:10.1038/nature09929.
   PubMed Web of Science ®Google Scholar
• Ebo JS, Saunders JC, Devine PWA, Gordon AM, Warwick AS, Schiffrin B, Chin SE, England E, Button JD, Lloyd C. An in vivo platform to select and evolve aggregation-resistant proteins. Nat Commun. 2020;11(1):1–12. doi:10.1038/s41467-020-15667-1.
   PubMed Web of Science ®Google Scholar
• Wang T, Badran AH, Huang TP, Liu DR. Continuous directed evolution of proteins with improved soluble expression. Nat Chem Biol. 2018;14(10):972–80. doi:10.1038/s41589-018-0121-5.
   PubMed Web of Science ®Google Scholar
• Morrison MS, Wang T, Raguram A, Hemez C, Liu DR. Disulfide-compatible phage-assisted continuous evolution in the periplasmic space. Nat Commun. 2021;12(1):1–14. doi:10.1038/s41467-021-26279-8.
   PubMed Web of Science ®Google Scholar
• Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE, et al. An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol. 2016;12(2):94–101. doi:10.1038/nchembio.1988.
   PubMed Web of Science ®Google Scholar
• Wellner A, McMahon C, Gilman MSA, Clements JR, Clark S, Nguyen KM, Ho MH, Hu VJ, Shin J-E, Feldman J, et al. Rapid generation of potent antibodies by autonomous hypermutation in yeast. Nat Chem Biol. 2021;17(10):1057–64. doi:10.1038/s41589-021-00832-4.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM, et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat Commun. 2022;13(1):1–14. doi:10.1038/s41467-022-31457-3.
   PubMed Web of Science ®Google Scholar
• Saksena SD, Liu G, Banholzer C, Horny G, Ewert S, Gifford DK. Computational counterselection identifies nonspecific therapeutic biologic candidates. Cell Reports Methods. 2022;2(7):100254. doi:10.1016/j.crmeth.2022.100254.
   PubMedGoogle Scholar
• Liu G, Zeng H, Mueller J, Carter B, Wang Z, Schilz J, Horny G, Birnbaum ME, Ewert S, Gifford DK, et al. Antibody complementarity determining region design using high-capacity machine learning. Bioinformatics. 2020;36(7):2126–33. doi:10.1093/bioinformatics/btz895.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Chen H, Lambert M, Bennett EM, Eschmann N, Zhang Y, Zupancic JM, Desai AA, Smith MD, Lou W. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning. MAbs. 2022;14(1). doi:10.1080/19420862.2022.2146629
   PubMed Web of Science ®Google Scholar
• Julian MC, Li L, Garde S, Wilen R, Tessier PM. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability. Sci Rep. 2017;7(1):1–13. doi:10.1038/srep45259.
   PubMedGoogle Scholar
• Shehata L, Maurer DP, Wec AZ, Lilov A, Champney E, Sun T, Archambault K, Burnina I, Lynaugh H, Zhi X, et al. Affinity maturation enhances antibody specificity but compromises conformational stability. Cell Rep. 2019;28(13):3300–08. doi:10.1016/j.celrep.2019.08.056.
   PubMed Web of Science ®Google Scholar
• Traxlmayr MW, Faissner M, Stadlmayr G, Hasenhindl C, Antes B, Rüker F, Obinger C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim Biophys Acta Proteins Proteom. 2012;1824(4):542–49. doi:10.1016/j.bbapap.2012.01.006.
   Web of Science ®Google Scholar
• Traxlmayr MW, Obinger C. Directed evolution of proteins for increased stability and expression using yeast display. Arch Biochem Biophys. 2012;526(2):174–80. doi:10.1016/j.abb.2012.04.022.
   PubMed Web of Science ®Google Scholar
• Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs. 2013;5(2):237–54. doi:10.4161/mabs.23363.
   PubMed Web of Science ®Google Scholar
• Luo R, Qu B, An L, Zhao Y, Cao Y, Ren P, Hang H. Simultaneous maturation of single chain antibody stability and affinity by CHO cell display. Bioengineering. 2022;9(8):360. doi:10.3390/bioengineering9080360.
   PubMedGoogle Scholar
• Mason DM, Friedensohn S, Weber CR, Jordi C, Wagner B, Meng SM, Ehling RA, Bonati L, Dahinden J, Gainza P, et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat Biomed Eng. 2021;5(6):600–12. doi:10.1038/s41551-021-00699-9.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7(4):770–77. doi:10.1080/19420862.2015.1043503/SUPPL_FILE/KMAB_A_1043503_SM9491.ZIP.
   PubMed Web of Science ®Google Scholar
• Watson CD, Ford HC. High-affinity binding of riboflavin and FAD by immunoglobulins from normal human serum. Biochem Int. 1988; 16(6):1067–74. [Accessed October 10, 2022]. https://europepmc.org/article/med/3178858.
   PubMedGoogle Scholar
• Bowen RAR, Drake SK, Vanjani R, Huey ED, Grafman J, Horne MK. Markedly increased vitamin B12 concentrations attributable to IgG-IgM-vitamin B12 immune complexes. Clin Chem. 2006;52(11):2107–14. doi:10.1373/clinchem.2006.073882.
   PubMed Web of Science ®Google Scholar
• Lecerf M, Kanyavuz A, Rossini S, Dimitrov JD. Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Commun Biol. 2021;4(1):1–13. doi:10.1038/s42003-021-01931-7.
   PubMed Web of Science ®Google Scholar
• Dimitrov JD, Ivanovska ND, Lacroix-Desmazes S, Doltchinkova VR, Kaveri SV, Vassilev TL. Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. Journal of Biological Chemistry. 2006;281(1):439–46. doi:10.1074/jbc.M509190200.
   PubMed Web of Science ®Google Scholar
• McIntyre JA. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation-reduction reactions. Thromb Res. 2004;114(5–6):579–87. doi:10.1016/j.thromres.2004.08.008.
   PubMedGoogle Scholar
• McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J Autoimmun. 2005;24(4):311–17. doi:10.1016/j.jaut.2005.03.005.
   PubMed Web of Science ®Google Scholar
• Lecerf M, Lacombe R, Kanyavuz A, Dimitrov JD. Functional changes of therapeutic antibodies upon exposure to pro-oxidative agents. Antibodies. 2022;11(1):11. doi:10.3390/antib11010011.
   Web of Science ®Google Scholar
• Gupta S, Jiskoot W, Schöneich C, Rathore AS. Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy. J Pharm Sci. 2022;111(4):903–18. doi:10.1016/j.xphs.2021.11.024.
   PubMed Web of Science ®Google Scholar
• Starr CG, Makowski EK, Wu L, Berg B, Kingsbury JS, Gokarn YR, Tessier PM. Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties. Mol Pharm. 2021;18(7):2744–53. doi:10.1021/acs.molpharmaceut.1c00280.
   PubMedGoogle Scholar
• Wu J, Schultz JS, Weldon CL, Sule SV, Chai Q, Geng SB, Dickinson CD, Tessier PM. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. Protein Engineering, Design and Selection. 2015;28(10):403–14. doi:10.1093/protein/gzv045.
   PubMed Web of Science ®Google Scholar
• Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm. 2013;10(4):1322–31. doi:10.1021/mp300524x.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6(2):483–92. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Fraunhofer W, Winter G. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. European Journal of Pharmaceutics and Biopharmaceutics. 2004;58(2):369–83. doi:10.1016/j.ejpb.2004.03.034.
   PubMed Web of Science ®Google Scholar
• Marioli M, Kok WT. Recovery, overloading, and protein interactions in asymmetrical flow field-flow fractionation. Anal Bioanal Chem. 2019;411(11):2327–38. doi:10.1007/s00216-019-01673-w.
   PubMed Web of Science ®Google Scholar
• Wahlund PO, Lorenzen N, Rischel C. Screening for protein–protein interactions with asymmetrical flow field-flow fractionation. J Pharm Sci. 2021;110(6):2336–39. doi:10.1016/J.XPHS.2021.02.026.
   PubMed Web of Science ®Google Scholar
• Das TK, Chou DK, Jiskoot W, Arosio P. Nucleation in protein aggregation in biotherapeutic development: a look into the heart of the event. J Pharm Sci. 2022;111(4):951–59. doi:10.1016/j.xphs.2022.01.017.
   PubMed Web of Science ®Google Scholar
• Wang W, Roberts CJ. Non-Arrhenius protein aggregation. AAPS Journal. 2013;15(3):840–51. doi:10.1208/s12248-013-9485-3.
   PubMed Web of Science ®Google Scholar
• Arosio P, Rima S, Morbidelli M. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates. Pharm Res. 2013;30(3):641–54. doi:10.1007/s11095-012-0885-3.
   PubMed Web of Science ®Google Scholar
• Wälchli R, Vermeire PJ, Massant J, Arosio P. Accelerated aggregation studies of monoclonal antibodies: considerations for storage stability. J Pharm Sci. 2020;109(1):595–602. doi:10.1016/j.xphs.2019.10.048.
   PubMed Web of Science ®Google Scholar
• Jgs H, Middelberg APJ. Estimating the potential refolding yield of recombinant proteins expressed as inclusion bodies. Biotechnol Bioeng. 2004;87(5):584–92. doi:10.1002/bit.20148.
   PubMed Web of Science ®Google Scholar
• Kunz P, Zinner K, Mücke N, Bartoschik T, Muyldermans S, Hoheisel JD. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci Rep. 2018;8(1):1–10. doi:10.1038/s41598-018-26338-z.
   PubMedGoogle Scholar
• Schön A, Freire E. Reversibility and irreversibility in the temperature denaturation of monoclonal antibodies. Anal Biochem. 2021;626:114240. doi:10.1016/j.ab.2021.114240.
   PubMed Web of Science ®Google Scholar
• Svilenov HL, Menzen T, Richter K, Winter G. Modulated scanning fluorimetry can quickly assess thermal protein unfolding reversibility in microvolume samples. Mol Pharm. 2020;17(7):2638–47. doi:10.1021/acs.molpharmaceut.0c00330.
   PubMedGoogle Scholar
• Svilenov H, Winter G. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage. European Journal of Pharmaceutics and Biopharmaceutics. 2019;137:131–39. doi:10.1016/j.ejpb.2019.02.018.
   PubMed Web of Science ®Google Scholar
• Svilenov H, Gentiluomo L, Friess W, Roessner D, Winter G. A new approach to study the physical stability of monoclonal antibody formulations—dilution from a denaturant. J Pharm Sci. 2018;107(12):3007–13. doi:10.1016/j.xphs.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Berner C, Menzen T, Winter G, Svilenov HL. Combining unfolding reversibility studies and molecular dynamics simulations to select aggregation-resistant antibodies. Mol Pharm. 2021;18(6):2242–53. doi:10.1021/acs.molpharmaceut.1c00017.
   PubMedGoogle Scholar
• Kopp MRG, Grigolato F, Zürcher D, Das TK, Chou D, Wuchner K, Arosio P. Surface-induced protein aggregation and particle formation in biologics: current understanding of mechanisms, detection and mitigation strategies.J Pharm Sci. - October 9 2022; Accepted manuscript, In press 10.1016/j.xphs.2022.10.009
   Web of Science ®Google Scholar
• Kopp MRG, Capasso Palmiero U, Arosio P. A nanoparticle-based assay to evaluate surface-induced antibody instability. Mol Pharm. 2020;17(3):909–18. doi:10.1021/acs.molpharmaceut.9b01168.
   PubMedGoogle Scholar
• Kopp MRG, Wolf Pérez AM, Zucca MV, Capasso Palmiero U, Friedrichsen B, Lorenzen N, Arosio P. An accelerated surface-mediated stress assay of antibody instability for developability studies. MAbs. 2020;12(1):1815995. doi:10.1080/19420862.2020.1815995.
   PubMed Web of Science ®Google Scholar
• Johann F, Wöll S, Winzer M, Snell J, Valldorf B, Gieseler H. Miniaturized forced degradation of therapeutic proteins and ADCs by agitation-induced aggregation using orbital shaking of microplates. J Pharm Sci. 2022;111(5):1401–13. doi:10.1016/j.xphs.2021.09.027.
   PubMed Web of Science ®Google Scholar
• Mathaes R, Narhi L, Hawe A, Matter A, Bechtold-Peters K, Kenrick S, Kar S, Laskina O, Carpenter J, Cavicchi R. Phase-appropriate application of analytical methods to monitor subvisible particles across the biotherapeutic drug product life cycle. AAPS Journal. 2020;22(1):1–7. doi:10.1208/s12248-019-0384-0.
   Web of Science ®Google Scholar
• Roesch A, Zölls S, Stadler D, Helbig C, Wuchner K, Kersten G, Hawe A, Jiskoot W, Menzen T. Particles in biopharmaceutical formulations, Part 2: an update on analytical techniques and applications for therapeutic proteins, viruses, vaccines and cells. J Pharm Sci. 2022;111(4):933–50. doi:10.1016/j.xphs.2021.12.011.
   PubMed Web of Science ®Google Scholar
• Kunz P, Stuckenberger E, Hausmann K, Gentiluomo L, Neustrup M, Michalakis S, Rieser R, Romeijn S, Wichmann C, Windisch R, et al. Understanding opalescence measurements of biologics – a comparison study of methods, standards, and molecules. Int J Pharm. 2022;628:122321. doi:10.1016/j.ijpharm.2022.122321.
   PubMedGoogle Scholar
• Helbig C, Ammann G, Menzen T, Friess W, Wuchner K, Hawe A. Backgrounded membrane imaging (BMI) for high-throughput characterization of subvisible particles during biopharmaceutical drug product development. J Pharm Sci. 2020;109(1):264–76. doi:10.1016/j.xphs.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Murphy MI, Bruque M, Hanford A, Trayton I, Handali M, Leissa JA, Hasige S, Day K, Patel SM. Qualitative High-throughput analysis of subvisible particles in biological formulations using backgrounded membrane imaging. J Pharm Sci. 2022;111(6):1605–13. doi:10.1016/j.xphs.2022.03.010.
   PubMed Web of Science ®Google Scholar
• Gühlke M, Hecht J, Böhrer A, Hawe A, Nikels F, Garidel P, Menzen T. Taking subvisible particle quantitation to the limit: uncertainties and statistical challenges with ophthalmic products for intravitreal injection. J Pharm Sci. 2020;109(1):505–14. doi:10.1016/j.xphs.2019.10.061.
   PubMed Web of Science ®Google Scholar
• Calderon CP, Levačić A K, Helbig C, Wuchner K, Menzen T. Combining machine learning and backgrounded membrane imaging: a case study in comparing and classifying different types of biopharmaceutically relevant particles. J Pharm Sci. 2022;111(9):2422–34. doi:10.1016/j.xphs.2022.05.022.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. Third generation antibody discovery methods: in silico rational design. Chem Soc Rev. 2018;47(24):9137–57. doi:10.1039/c8cs00523k.
   PubMed Web of Science ®Google Scholar
• Fischman S, Ofran Y. Computational design of antibodies. Curr Opin Struct Biol. 2018;51:156–62. doi:10.1016/j.sbi.2018.04.007.
   PubMed Web of Science ®Google Scholar
• Baran D, Pszolla MG, Lapidoth GD, Norn C, Dym O, Unger T, Albeck S, Tyka MD, Fleishman SJ. Principles for computational design of binding antibodies. Proc Natl Acad Sci U S A. 2017;114(41):10900–05. doi:10.1073/pnas.1707171114.
   PubMed Web of Science ®Google Scholar
• Nimrod G, Fischman S, Austin M, Herman A, Keyes F, Leiderman O, Hargreaves D, Strajbl M, Breed J, Klompus K. Computational design of epitope-specific functional antibodies. Cell Rep. 2018;25(8):2121–31. doi:10.1016/j.celrep.2018.10.081.
   PubMed Web of Science ®Google Scholar
• Entzminger KC, Hyun JM, Pantazes RJ, Patterson-Orazem AC, Qerqez AN, Frye ZP, Hughes RA, Ellington AD, Lieberman RL, Maranas CD. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide. Sci Rep. 2017;7(1):1–11. doi:10.1038/s41598-017-10737-9.
   PubMedGoogle Scholar
• Poosarla VG, Li T, Goh BC, Schulten K, Wood TK, Maranas CD. Computational de novo design of antibodies binding to a peptide with high affinity. Biotechnol Bioeng. 2017;114(6):1331–42. doi:10.1002/bit.26244.
   PubMed Web of Science ®Google Scholar
• Pras A The Molecular Role of SERF in Amyloid Formation: A Fine Line between Toxicity and Function. PhD Thesis. 2021. doi:10.33612/diss.177554757
   Google Scholar
• Aprile FA, Sormanni P, Podpolny M, Chhangur S, Needham L-M, Ruggeri FS, Perni M, Limbocker R, Heller GT, Sneideris T, et al. Rational design of a conformation-specific antibody for the quantification of Aβ oligomers. Proc Natl Acad Sci U S A. 2020;117(24):13509–18. doi:10.1073/pnas.1919464117.
   PubMed Web of Science ®Google Scholar
• Lin J, Figazzolo C, Metrick MA, Sormanni P, Vendruscolo M. Computational maturation of a single-domain antibody against Aβ42 aggregation. Chem Sci. 2021;12(41):13940–48. doi:10.1039/d1sc03898b.
   PubMed Web of Science ®Google Scholar
• Kulenkampff K, Emin D, Staats R, Zhang YP, Sakhnini L, Kouli A, Rimon O, Lobanova E, Williams-Gray CH, Aprile FA, et al. An antibody scanning method for the detection of α-synuclein oligomers in the serum of Parkinson’s disease patients. Chem Sci. 2022;13(46):13815–28. doi:10.1039/d2sc00066k.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc Natl Acad Sci U S A. 2015;112(32):9902–07. doi:10.1073/pnas.1422401112.
   PubMed Web of Science ®Google Scholar
• Aguilar Rangel M, Bedwell A, Costanzi E, Taylor RJ, Russo R, Bernardes GJL, Ricagno S, Frydman J, Vendruscolo M, Sormanni P, et al. Fragment-based computational design of antibodies targeting structured epitopes. Sci Adv. 2022;8(45):9540. doi:10.1126/SCIADV.ABP9540/SUPPL_FILE/SCIADV.ABP9540_TABLE_S3.ZIP.
   Web of Science ®Google Scholar
• Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs. 2022;14(1):2020082. doi:10.1080/19420862.2021.2020082.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116(10):4025–30. doi:10.1073/pnas.1810576116.
   PubMed Web of Science ®Google Scholar
• Thorsteinson N, Gunn JR, Kelly K, Long W, Labute P. Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics. MAbs. 2021;13(1):1981805. doi:10.1080/19420862.2021.1981805.
   PubMed Web of Science ®Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc Natl Acad Sci U S A. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118.
   PubMed Web of Science ®Google Scholar
• Broom A, Jacobi Z, Trainor K, Meiering EM. Computational tools help improve protein stability but with a solubility tradeoff. Journal of Biological Chemistry. 2017;292(35):14349–61. doi:10.1074/jbc.M117.784165.
   PubMed Web of Science ®Google Scholar
• Gil-Garcia M, Banó-Polo M, Varejao N, Jamroz M, Kuriata A, Díaz-Caballero M, Lascorz J, Morel B, Navarro S, Reverter D, et al. Combining structural aggregation propensity and stability predictions to redesign protein solubility. Mol Pharm. 2018;15(9):3846–59. doi:10.1021/acs.molpharmaceut.8b00341.
   PubMedGoogle Scholar
• van der Kant R, Karow-Zwick AR, van Durme J, Blech M, Gallardo R, Seeliger D, Aßfalg K, Baatsen P, Compernolle G, Gils A, et al. Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol. 2017;429(8):1244–61. doi:10.1016/j.jmb.2017.03.014.
   PubMed Web of Science ®Google Scholar
• Rosace A, Bennett A, Oeller M, Mortensen MM, Sakhnini LI, Sormanni P. Automated optimisation of solubility and conformational stability of antibodies and proteins. bioRxiv. Published online October 18, 2022. doi:10.1101/2022.05.20.492798.
   Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol. 2015;427(2):478–90. doi:10.1016/j.jmb.2014.09.026.
   PubMed Web of Science ®Google Scholar
• Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33(SUPPL. 2):W382–W388. doi:10.1093/nar/gki387.
   PubMedGoogle Scholar
• Abanades B, Georges G, Bujotzek A, Deane CM, Xu J. ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics. 2022;38(7):1877–80. doi:10.1093/bioinformatics/btac016.
   PubMed Web of Science ®Google Scholar
• Ruffolo JA, Sulam J, Gray JJ. Antibody structure prediction using interpretable deep learning. Patterns. 2022;3(2):100406. doi:10.1016/j.patter.2021.100406.
   PubMedGoogle Scholar
• Cohen T, Halfon M, Schneidman-Duhovny D. NanoNet: rapid and accurate end-to-end nanobody modeling by deep learning. Front Immunol. 2022;13:4319. doi:10.3389/fimmu.2022.958584.
   Web of Science ®Google Scholar
• Schneider C, Raybould MIJ, Deane CM. SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker. Nucleic Acids Res. 2022;50(D1):D1368–D1372. doi:10.1093/nar/gkab1050.
   PubMed Web of Science ®Google Scholar
• Liberis E, Velickovic P, Sormanni P, Vendruscolo M, Lio P, Hancock J. Parapred: antibody paratope prediction using convolutional and recurrent neural networks. Bioinformatics. 2018;34(17):2944–50. doi:10.1093/bioinformatics/bty305.
   PubMed Web of Science ®Google Scholar
• Deac A, Veličković P, Sormanni P. Attentive Cross-Modal Paratope Prediction. Journal of Computational Biology. 2019;26(6):536–45. doi:10.1089/cmb.2018.0175.
   PubMed Web of Science ®Google Scholar
• Leem J, Mitchell LS, Farmery JHR, Barton J, Galson JD. Deciphering the language of antibodies using self-supervised learning. Patterns. 2022;3(7):100513. doi:10.1016/j.patter.2022.100513.
   PubMedGoogle Scholar
• Kopp MRG, Arosio P. Microfluidic Approaches for the Characterization of Therapeutic Proteins. J Pharm Sci. 2018;107(5):1228–36. doi:10.1016/j.xphs.2018.01.001.
   PubMed Web of Science ®Google Scholar
• Erkamp NA, Oeller M, Sneideris T, Ausserwӧger H, Levin A, Welsh T, Qi R, Qian D, Zhu H, Sormanni P. Multi-dimensional protein solubility optimization with an ultra-high-throughput microfluidic platform. bioRxiv. Published online October 22 2022. 10.1101/2022.10.21.513267. 2022.10.21.513267.
   Google Scholar
• Narayanan H, Dingfelder F, Condado Morales I, Patel B, Heding KE, Bjelke JR, Egebjerg T, Butté A, Sokolov M, Lorenzen N, et al. Design of biopharmaceutical formulations accelerated by machine learning. Mol Pharm. 2021;18(10):3843–53. doi:10.1021/acs.molpharmaceut.1c00469.
   PubMedGoogle Scholar
• Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372(6545):916–17. doi:10.1126/science.abg1209.
   PubMed Web of Science ®Google Scholar
• Sawant MS, Streu CN, Wu L, Tessier PM. Toward drug-like multispecific antibodies by design. Int J Mol Sci. 2020;21(20):1–41. doi:10.3390/ijms21207496.
   Web of Science ®Google Scholar
• Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, Tischler M, Wagner M, Kuglstatter A, Leibrock L, et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11(1):1–11. doi:10.1038/s41467-020-18477-7.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789–805. doi:10.1016/j.cell.2022.05.029.
   PubMed Web of Science ®Google Scholar